ON APRIL 29, 2004, NAVH CELEBRATED ITS 50TH ANNIVERSARY. THIS EXCITING EVENT HONORED OUR FOUNDER/CEO, DR. LORRAINE MARCHI AND LEADING OPHTHALMOLOGIST DR. RICHARD SPAIDE OF VITREOUS, RETINA, MACULA CONSULTANTS OF NEW YORK.

Make a tax-deductible donation to NAVH and help us continue to supply services to those of limited means.

MEMBERSHIP

We thank you for your support.
 

NAVH UPDATE

AMD TREATMENT UPDATE - Jason S. . Over the last few years, excitement over a growing number of potential new treatments for the exudative or wet form of age-related macular degeneration has been growing. It’s important to keep in mind, however, that as of today, there are still only two therapeutic approaches which have been proven in large-scale clinical trial and have been approved by the FDA. These remain laser photocoagulation treatment (so called “hot laser”) and photodynamic therapy with Verteporfin (Visudyne therapy or so called “cold laser”). Laser photocoagulation is still used for blood vessels which occur outside the center of vision, while photodynamic therapy is used for blood vessels which occur under the center. Both of these therapies, while successful in many patients, are still limited in their ability to restore vision.      In order to receive the complete article, email navh@navh.org, call (212) 255-2804 or write to register as a recipient of UPDATE our quarterly newsletter. You can also request a number of complimentary copies, as you like.   ©'1997-2004